Iambic Therapeutics Surges 17% After-Hours as Wall Street Backs AI-Powered Drug Discovery Platform

Wall Street Analysts Turn Bullish on Iambic Therapeutics

Iambic Therapeutics (NASDAQ: IAM) shares surged 16.82% to $15.63 in after-hours trading on Monday after two major Wall Street analysts initiated coverage with buy ratings on the clinical-stage biotechnology company. BofA Securities set a $30 price target while Jefferies established a $35 price target, signaling strong confidence in the company's AI-powered drug discovery platform1

1

2

2

. The stock closed regular trading at $13.38, up 31.56% from its previous close of $10.17, though it remains below its 52-week high of $251

1

.

Proprietary AI Models Distinguish Iambic's Approach

BofA Securities highlighted Iambic Therapeutics' distinctive approach to AI drug discovery, emphasizing how the company uses proprietary AI models combined with automated chemistry to design cancer drugs rather than simply identifying disease targets. This methodology could significantly shorten drug development timelines and reduce costs, setting Iambic apart from other AI-driven drug developers in the market1

1

. The company's platform, which it calls molecular superintelligence, integrates proprietary AI technologies with automated chemistry platform and biology experimentation to accelerate drug development1

1

.

IAM1363 Shows Promise in HER2-Positive Breast Cancer

Jefferies pointed to early clinical data from IAM1363, a HER2 tyrosine kinase inhibitor, which has demonstrated encouraging activity in heavily pretreated patients with HER2-positive breast cancer brain metastases. The drug candidate advanced to clinical development in approximately two years, showcasing the efficiency of Iambic's AI drug discovery approach1

1

2

2

. However, Jefferies noted that IAM1363's superiority over newer HER2 tyrosine kinase inhibitors remains unproven, though the firm sees upside potential from replacing tucatinib in HER2CLIMB-like regimens or combination with Zani2

2

.

Platform Scalability Could Offset R&D Costs

Jefferies initiates coverage with particular emphasis on the AI-powered drug discovery platform's potential to scale and offset R&D costs. At Iambic's current market capitalization of approximately $600 million, Jefferies modeled risk-adjusted peak sales of approximately $870 million for IAM1363, $180 million for IAM217, $260 million for IAMC1, and $250 million for the AI platform itself2

2

. The company operates a drug development-as-a-service model that supports both internal pipeline development and external partnerships, creating multiple revenue streams from its technology2

2

.

CEO to Present at Jefferies Global Healthcare Conference

Iambic Therapeutics announced that Co-Founder and CEO Tom Miller will participate in the Jefferies Global Healthcare Conference scheduled for November 16-19 in London. Miller will join a panel discussion on AI in drug discovery on November 18 at 2:00 p.m. GMT1

1

. Miller emphasized that the opportunity for AI in drug discovery lies in integrating insights across chemistry, biology and clinical development to improve the probability of developing successful medicines1

1

. The company's preclinical pipeline includes AI technologies such as Enchant and NeuralPLexer, designed to enhance drug development and clinical development processes1

1

.